Ekaterina Baron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ekaterina Baron has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Armando Sardi
Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, 227 St. Paul Place, 4th Floor Weinberg, Baltimore, MD 21202-2001 USA
23 shared publications - Vadim Gushchin
Department of Surgical Oncology, Mercy Medical Center, The Institute for Cancer Care, Baltimore, USA
22 shared publications - Andrei Nikiforchin
Mercy Medical Center, The Institute for Cancer Care, Department of Surgical Oncology, 227 St. Paul Place, Weinberg Building, 4th Floor, Baltimore, MD, 21202-2001, USA
21 shared publications - Mary Caitlin King
Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, 227 St. Paul Place, 4th Floor Weinberg, Baltimore, MD, 21202-2001, USA
18 shared publications - Felipe Lopez-Ramirez
The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, USA
13 shared publications - Michelle Sittig
Department of Surgical Oncology, The Institute for Cancer Care, Mercy Medical Center, Baltimore, USA
10 shared publications
Latest Publications
- 24 December 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (3) , 2304-2312
Robotic versus open cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a propensity score-matched study
Background Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is often associated with extensive surgical resection and has traditionally been performed via laparotomy. Data on minimally invasive robotic approaches remain limited. We evaluated surgical safety and survival outcomes of robotic CRS/HIPEC for peritoneal surface malignancies (PSM). Methods A single-center propensity score-matched study was conducted using a prospectively collected database (2018–2025). PSM patients treated with robotic CRS/HIPEC were matched 1:1 to open CRS/HIPEC controls using propensity scores based on age, sex, BMI, histology, and PCI. Results Of 99 cases, 15 robotic and 71 open CRS/HIPECs were identified. After matching, 15 robotic and 15 open cases were balanced by age, sex, BMI, diagnosis, prior surgical score, and PCI. CC-0/1 rate was 100.0% in robotic and 93.3% in open CRS/HIPEC (p = 1.00). Median blood loss was lower in the robotic group (100 mL vs 250 mL, p = 0.04). Median hospital stay was shorter after robotic CRS/HIPEC (6 vs 9 days, p = 0.05). No differences were observed in major complications (26.7% vs 33.3%, p = 1.00) and reoperation (0.0% vs 6.7%, p = 1.00). No 90-day mortality was observed in either group. Median follow-up was 58 months. Median overall survival (not reached vs 52 months, p = 0.20) and progression-free survival (not reached vs 42 months, p = 0.19) did not differ between robotic and open CRS/HIPEC. Conclusion In PSM patients with low tumor burden, robotic CRS/HIPEC is not associated with increased morbidity or worse survival. It may offer benefits such as reduced blood loss and shorter hospitalization. Multicenter studies are warranted to optimize patient selection.
- 24 December 2025
- Published by Springer Nature in Surgical Endoscopy
- Vol. 40 (3) , 2304-2312
Robotic versus open cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a propensity score-matched study
Background Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is often associated with extensive surgical resection and has traditionally been performed via laparotomy. Data on minimally invasive robotic approaches remain limited. We evaluated surgical safety and survival outcomes of robotic CRS/HIPEC for peritoneal surface malignancies (PSM). Methods A single-center propensity score-matched study was conducted using a prospectively collected database (2018–2025). PSM patients treated with robotic CRS/HIPEC were matched 1:1 to open CRS/HIPEC controls using propensity scores based on age, sex, BMI, histology, and PCI. Results Of 99 cases, 15 robotic and 71 open CRS/HIPECs were identified. After matching, 15 robotic and 15 open cases were balanced by age, sex, BMI, diagnosis, prior surgical score, and PCI. CC-0/1 rate was 100.0% in robotic and 93.3% in open CRS/HIPEC (p = 1.00). Median blood loss was lower in the robotic group (100 mL vs 250 mL, p = 0.04). Median hospital stay was shorter after robotic CRS/HIPEC (6 vs 9 days, p = 0.05). No differences were observed in major complications (26.7% vs 33.3%, p = 1.00) and reoperation (0.0% vs 6.7%, p = 1.00). No 90-day mortality was observed in either group. Median follow-up was 58 months. Median overall survival (not reached vs 52 months, p = 0.20) and progression-free survival (not reached vs 42 months, p = 0.19) did not differ between robotic and open CRS/HIPEC. Conclusion In PSM patients with low tumor burden, robotic CRS/HIPEC is not associated with increased morbidity or worse survival. It may offer benefits such as reduced blood loss and shorter hospitalization. Multicenter studies are warranted to optimize patient selection.
- 26 November 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (1) , 111301
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal carcinoma with peritoneal and parenchymal metastases
- 26 November 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (1) , 111301
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal carcinoma with peritoneal and parenchymal metastases
- 21 October 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (1) , 110536
Controlling perfusion temperature relates to better outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
- 21 October 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 52 (1) , 110536
Controlling perfusion temperature relates to better outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
- 3 February 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (5) , 109675
Prognostic value of preoperative serum C-reactive protein level for survival in mucinous appendix cancer treated with complete CRS/HIPEC
- 3 February 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (5) , 109675
Prognostic value of preoperative serum C-reactive protein level for survival in mucinous appendix cancer treated with complete CRS/HIPEC
- 2 May 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (7) , 4201-4202
ASO Author Reflections: Shaping Paraganglioma Management from Operating Rooms to Genetic Labs
- 2 May 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (7) , 4201-4202
ASO Author Reflections: Shaping Paraganglioma Management from Operating Rooms to Genetic Labs
- 13 April 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (7) , 4197-4198
Paraaortic Extra-Adrenal Paraganglioma: Challenging Robotic Resection
Up to 41% of intra- and extra-adrenal paragangliomas are linked to germline mutations with autosomal dominant transmission, which necessitates genetic test
- 13 April 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (7) , 4197-4198
Paraaortic Extra-Adrenal Paraganglioma: Challenging Robotic Resection
Up to 41% of intra- and extra-adrenal paragangliomas are linked to germline mutations with autosomal dominant transmission, which necessitates genetic test
- 2 January 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (2) , 107948
Collaborative expertise of gynecological and surgical oncologists in managing advanced epithelial ovarian cancer
- 2 January 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (2) , 107948
Collaborative expertise of gynecological and surgical oncologists in managing advanced epithelial ovarian cancer
- 30 March 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (8) , 1495-1503
Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma
- 30 March 2023
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (8) , 1495-1503
Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal dissemination from ovarian carcinosarcoma
- 2 September 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (1) , 179-187
Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
- 2 September 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 49 (1) , 179-187
Adjuvant chemotherapy for high-grade appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
- 22 June 2022
- Published by Springer Nature in Annals of Surgical Oncology
ASO Visual Abstract: Systemic Chemotherapy in High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread after Unsuccessful Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
Colon-type systemic chemotherapy is associated with longer survival in patients with high-grade mucinous appendiceal cancer with unresectable peritoneal metastases who were deemed surgical candidates but had a failed attempt of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (https://doi.org/10.1245/s10434-022-11894-6).
- 22 June 2022
- Published by Springer Nature in Annals of Surgical Oncology
ASO Visual Abstract: Systemic Chemotherapy in High-Grade Mucinous Appendiceal Cancer with Peritoneal Spread after Unsuccessful Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
Colon-type systemic chemotherapy is associated with longer survival in patients with high-grade mucinous appendiceal cancer with unresectable peritoneal metastases who were deemed surgical candidates but had a failed attempt of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (https://doi.org/10.1245/s10434-022-11894-6).